PDS Biotechnology stock analysis
Want to see PDSB full AI Analyst Report?
PDS Biotechnology (PDSB) Stock Price & Analysis
PDSB Stock Chart & Stats
- Day’s Range
- $0.76 - $0.92
- 52-Week Range
- $0.20 - $1.79
- Previous Close
- $0.89
- Volume
- N/A
- Average Volume (3M)
- 7.00M
- Market Cap
- $82.33M
- Enterprise Value
- $38.79M
- Total Cash (Recent Filing)
- $15.25B
- Total Debt (Recent Filing)
- $33.52M
- Price to Earnings (P/E)
- ―
- Beta
- 2.76
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Promising PDS0301 Clinical Data
Encouraging Phase 2 outcomes in difficult-to-treat metastatic colorectal cancer support PDS0301’s potential clinical differentiation. The data provide a basis for designing a registrational Phase 3 program and may improve partnering prospects if durability and benefit are confirmed.
Validated PDS0101 Oncology Results
The PDS0101 data indicate meaningful activity in HPV16-positive head and neck cancer, a focused indication with substantial unmet need. External interest and a negotiation window with NantWorks could help fund later development and preserve strategic optionality.
Strategic Financing And Debt Retirement
Debt retirement simplifies obligations while new financing supports working capital and continued clinical development. Nant-linked funding commitments and a potential PDS0101 licensing relationship may provide strategic support as the company advances its lead program toward later-stage testing.
Bears Say
Persistent Pre-revenue Losses
PDS Biotechnology has not yet demonstrated commercial revenue or operating leverage, leaving financial performance dependent on future clinical and regulatory success. Persistent losses increase the time and capital required before the pipeline can become self-sustaining.
Ongoing Cash Burn And Funding Dependence
Continued operating cash outflows mean the company cannot currently fund development from internal operations. It must rely on equity, debt, partnerships, or other external capital, creating recurring financing exposure as clinical programs become more expensive.
Constrained Financing Flexibility
Lender-protective financing terms restrict how new capital can be deployed and reduce management’s flexibility during a capital-intensive development period. This can limit resources available for operations or trials and increase dependence on additional financing.
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology’s price range in the past 12 months?
What is PDS Biotechnology’s market cap?
When is PDS Biotechnology’s upcoming earnings report date?
How were PDS Biotechnology’s earnings last quarter?
Is PDS Biotechnology overvalued?
Does PDS Biotechnology pay dividends?
What is PDS Biotechnology’s EPS estimate?
How many shares outstanding does PDS Biotechnology have?
What happened to PDS Biotechnology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PDS Biotechnology?
What is the TipRanks Smart Score and how is it calculated?
PDS Biotechnology Stock Smart Score
Company Description
PDS Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frank K. Bedu-Addo
- Employees
- 21
- Website
- www.pdsbiotech.com
- Address
- 303A College Road East, Princeton, NJ, 08540, US
PDS Biotechnology (PDSB) Earnings & Revenues
PDSB Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.
View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 1 | 0 | 11 |











